Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
221-240 of 936 trials

Advanced Solid Tumors: PF-08046054/SGN-PDL1V Study

We are investigating a new treatment for patients with advanced solid tumors. The goal is to see if it can improve outcomes compared to current therapies.

Non-small Cell Lung CancerOesophageal Squamous Cell CarcinomaGastric Cancer>2 yearsSafety phase (I)Oncology

Non-Hodgkin Lymphoma: BMS-986458 Treatment Study

We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

Metastatic Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Glioblastoma: [177Lu]Lu-DOTA-TATE Treatment Study

We are exploring a new drug for patients with newly diagnosed glioblastoma alongside standard care, and for those with recurrent glioblastoma as a single treatment. The goal is to find the best dose for effective treatment.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Solid Tumors: AZD3470 Study

We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.

Advanced Metastatic Solid Tumors (MTAP Deficient)Safety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: STX-721/PFL-721 Treatment

We are studying a new treatment for people with non-small cell lung cancer who have specific mutations. The goal is to see if it can improve their condition compared to standard therapies.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

CP-506 for Solid Tumors: A New Treatment Study

We are testing a new drug, CP-506, in patients with specific solid tumors to see how safe it is and how well it works. This study may help those with tumors that have certain genetic features or who are not responding well to current treatments.

Solid Tumors with DNA Repair Deficiencies>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Recurrent Gynecological Cancers: IMGN151 Study

We are testing a new drug, IMGN151, in women with recurrent gynecological cancers to assess its safety and determine the best dose. This study aims to understand how well the drug works and its effects on patients.

Recurrent Gynecological Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Solid Tumors: IMA401 TCER® Treatment

We are testing a new bispecific T-cell receptor treatment for patients with solid tumors. The study looks at its effects alone and with a checkpoint inhibitor to see how well it works.

Solid Tumors>2 yearsSafety phase (I)Oncology

Multiple Myeloma: Etentamig with Cancer Treatments

We are studying a new drug, Etentamig, combined with standard cancer therapies for adults with relapsed or refractory multiple myeloma. The goal is to assess its safety and impact on disease activity.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Chronic Obstructive Pulmonary Disease: GSK3862995B Study

We are investigating a new treatment for Chronic Obstructive Pulmonary Disease in both healthy individuals and those with the condition. This study aims to understand how the treatment may work in different populations.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsSafety phase (I)Pulmonology

Metastatic Breast Cancer: BGB-43395 Study

We are investigating a new drug for patients with metastatic HR+/HER2- breast cancer and other advanced solid tumors. The study aims to evaluate its safety and early signs of effectiveness, both alone and with other treatments.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Cleft Palate Treatment: Tissue-Engineered Oral Mucosa Substitute

We are testing a new tissue-engineered substitute for patients with cleft palate to see if it is safe and effective for healing and improving quality of life. The study will compare outcomes with standard treatments.

Cleft Lip and Palate>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyOrthopedics and TraumatologyPediatrics

Myeloid Malignancies: PF-08046040/SEA-CD70

We are studying the safety of a new treatment for patients with myeloid malignancies. This research aims to understand how well the treatment is tolerated by patients.

Acute Myeloid LeukaemiaMyelodysplastic Syndrome>2 yearsSafety phase (I)HematologyOncology

Non-Hodgkin Lymphoma: IPH6501 Treatment Study

We are investigating a new drug, IPH6501, for patients with relapsed or refractory Non-Hodgkin Lymphoma. The study focuses on its safety and early signs of effectiveness in treating this type of cancer.

Refractory Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Prostate Cancer: Pembrolizumab Combination Therapy

We are studying a new combination therapy with pembrolizumab for men with metastatic castration-resistant prostate cancer. The trial aims to evaluate its safety and how well it reduces PSA levels compared to standard treatments.

Metastatic Castration-Resistant Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Multiple Myeloma: TNB-383B Treatment Study

We are evaluating a new treatment for patients with multiple myeloma to see how safe it is and how well it works. This study will help us understand the maximum dose that can be tolerated.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology

Primary Cold Agglutinin Disease: ANX1502 Treatment Study

We are assessing a new treatment, ANX1502, for individuals with Primary Cold Agglutinin Disease. This study aims to understand its safety and how it affects the condition.

Cold Agglutinin Disease1-2 yearsSafety phase (I)HematologyInternal Medicine